FDA approves Merck's two-drug HIV pill Idvynso
The FDA has approved Merck's Idvynso, a once-daily two-drug HIV pill combining doravirine and islatravir, for adults already suppressing the virus on stable therapy. This marks a shift from standard three-drug regimens, potentially reducing side effects and drug interactions. The approval is based on clinical trials showing non-inferior efficacy compared to existing treatments. Merck plans to market Idvynso as a streamlined option for maintenance therapy.
Key facts
- FDA approved Idvynso on [date not specified]
- Idvynso combines doravirine and islatravir
- Indicated for adults with HIV suppression on stable therapy
- First two-drug regimen from Merck for HIV maintenance
- Clinical trials demonstrated non-inferior efficacy
- Reduces pill burden compared to three-drug regimens
- May lower risk of long-term side effects
- Manufactured by Merck & Co.
Entities
Institutions
- Merck & Co.
- FDA
Sources
- Quartz —